$0.58
-0.01 (-1.30%)
Open$0.59
Previous Close$0.58
Day High$0.60
Day Low$0.57
52W High$5.33
52W Low$0.40
Volume—
Avg Volume248.3K
Market Cap57.24M
P/E Ratio—
EPS$-0.89
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+3,234.5% upside
Current
$0.58
$0.58
Target
$19.24
$19.24
$16.83
$19.24 avg
$29.48
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 214.19M | 150.00M | 27.35M |
| Net Income | -66,556,171 | -41,950,104 | 6.20M |
| Profit Margin | -31.1% | -29.5% | 22.7% |
| EBITDA | -12,291,414 | -8,177,633 | 9.44M |
| Free Cash Flow | — | — | 4.10M |
| Rev Growth | +42.8% | +42.8% | -0.5% |
| Debt/Equity | 4.00 | 4.00 | 0.99 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $262.82 | +1.11% | 72.8 | 459.33B |
| AMGN | Amgen Inc | $403.04 | -1.04% | 25.1 | 219.33B |
| GILD | Gilead Sciences Inc | $144.74 | -1.87% | — | 179.15B |
| VRTX | Vertex Pharmaceuticals Inc | $504.73 | -0.40% | 30.1 | 132.51B |
| REGN | Regeneron Pharmaceuticals | $735.20 | +0.05% | 17.4 | 75.36B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.72 | -4.96% | 36.9 | 29.82B |